The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab

Hepatobiliary Surg Nutr. 2023 Feb 28;12(1):148-150. doi: 10.21037/hbsn-22-280. Epub 2023 Jan 16.
No abstract available

Publication types

  • Comment